XCancer Omaha LLC

1. Novartis Pharmaceuticals Corporation $1,223,550 11 payments
2. Bayer HealthCare Pharmaceuticals Inc. $877,891 24 payments
3. Exelixis Inc. $859,270 66 payments
4. Janssen Research & Development, LLC $391,038 70 payments
5. AstraZeneca Pharmaceuticals LP $226,479 1 payment
6. Pfizer Inc. $73,339 29 payments
7. Veru Inc. $52,851 21 payments
8. Telix Pharmaceuticals $43,116 6 payments
9. Dendreon Pharmaceuticals LLC $27,518 1 payment
10. Astellas Pharma Global Development $23,453 59 payments

1. An Open-Label, Randomized, Phase III Study Comparing 177Lu-Psma-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (Mhspc) $973,376 3 payments
2. A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors $635,705 34 payments
3. BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical $455,620 12 payments
4. BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer $394,521 10 payments
5. A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy $315,205 26 payments
6. a phase I,first in human,dose escalation study of 225ac AZD2284 in patients with metastatic castration resistant prostate cancer $226,479 1 payment
7. A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors $194,965 25 payments
8. A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) $120,000 2 payments
9. A Phase II, Open-label, Multi-Center, Randomized Study Comparing the Combination of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) and Androgen Receptor Pathway Inhibitor (ARPI) vs. Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in First-line Treatment $64,000 1 payment
10. Veracity - Randomized, Active-Controlled, Phase 3 Study of Veru-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent $52,851 21 payments

1. Non-patient care $7,950 20 payments
2. Patient care $6,494 5 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.